For most of the past two decades, White children in the United States had the highest diagnosed rates of autism. That pattern has shifted. Recent CDC surveillance data shows that autism prevalence among Black, Hispanic, and Asian/Pacific Islander children has risen sharply and, at many monitoring sites, now meets or exceeds the rate among White children. This change reflects improvements in screening and awareness rather than a true difference in who develops autism.
The short answer is that no single race is biologically more likely to have autism. What the data actually captures is who gets diagnosed, and that number is shaped by access to healthcare, cultural attitudes, income, and how well screening tools work across different populations.
How Diagnosis Rates Have Changed Over Time
Throughout the 2000s and into the early 2010s, White children consistently had the highest autism prevalence in CDC data. This wasn’t because autism was rarer in other groups. It was because White families, on average, had better access to developmental specialists, earlier pediatric screening, and the resources to navigate a complex diagnostic process. The gap was a measurement artifact, not a biological reality.
Over the past decade, public health efforts to screen children more broadly have started to close that gap. CDC surveillance from recent years shows autism prevalence rising fastest among Black, Hispanic, and Asian/Pacific Islander children. At many of the 16 monitoring sites in the CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network, these groups now have prevalence rates comparable to or higher than White children. The overall picture is one of convergence: as diagnostic access improves, the rates across racial groups are leveling out.
Why Minority Children Were Underdiagnosed for Years
Several overlapping barriers kept autism diagnosis rates artificially low in Black, Hispanic, and other minority communities. Understanding these barriers matters because they haven’t fully disappeared.
Black children, on average, don’t receive a diagnosis until three years after their parents first raise concerns about atypical behaviors. Part of the delay stems from cultural factors: mental health carries significant stigma in some Black communities, and parents may fear their child being labeled or treated differently. But the healthcare system itself shares blame. Black parents have reported pediatricians being dismissive of their concerns or attributing developmental differences to poor parenting or behavioral problems rather than recognizing potential autism. This pattern of implicit bias in clinical settings is well documented.
Medical mistrust also plays a role. A long history of unethical treatment in healthcare has left many Black families wary of the system, making them less likely to pursue evaluations even when a teacher or doctor suggests one. For Hispanic families, language barriers add another layer of difficulty. Navigating developmental evaluations, insurance systems, and specialist referrals is hard enough in English. For families who primarily speak Spanish or another language, the process can feel inaccessible.
Income and Education Shape Diagnosis Rates
Research published in the American Journal of Public Health analyzed autism prevalence among U.S. children from 2002 to 2010 and found a consistent pattern: diagnosis rates increased with socioeconomic status across all racial groups. Children in higher-income areas with better-educated parents were more likely to be diagnosed, regardless of whether they were White, Black, or Hispanic. The gap between the highest and lowest socioeconomic groups remained remarkably stable over that period, at roughly 4 per 1,000 children.
This SES gradient explains a lot of the racial differences in the data. Black and Hispanic families are disproportionately represented in lower-income brackets, where access to specialists is limited, wait times for evaluations are longer, and insurance coverage may not extend to the kind of comprehensive developmental testing that leads to an autism diagnosis. Even after researchers accounted for income differences, some racial disparities in diagnosis rates persisted, particularly among low-income children. This suggests that poverty and race compound each other, creating especially steep barriers for low-income minority families.
Screening Tools Don’t Work the Same Everywhere
The most widely used early screening tool for autism in toddlers, the M-CHAT, doesn’t perform equally well across all populations. A study synthesizing M-CHAT data from ten countries found that its sensitivity (its ability to correctly identify children who have autism) varied enormously, from as low as 18% in some Malaysian samples to over 90% in Iranian samples. Different countries and cultural groups flagged different items on the questionnaire as most important for identifying autism.
This matters because parents and caregivers from different cultural backgrounds may interpret and report their child’s behaviors differently. A behavior that one culture considers typical might be flagged as unusual in another, and vice versa. When a screening tool is developed and validated primarily on one population, it can miss children from other backgrounds or produce less reliable results. In the U.S., this means minority children may slip through early screening even when they do have access to pediatric care.
Global Prevalence Varies by Region
Looking beyond the U.S., the Global Burden of Disease Study 2021 estimated autism prevalence across world regions. North Africa and the Middle East had the highest estimated rate at roughly 772 per 100,000 people, followed by South Asia at about 686 per 100,000 and Southeast Asia, East Asia, and Oceania at around 669 per 100,000. The lowest estimated prevalence was in Bangladesh, at roughly 588 per 100,000.
These numbers are difficult to compare directly because they reflect the same diagnostic access problems seen within the U.S., just on a larger scale. Countries with robust healthcare systems and established screening programs identify more cases. Regions with limited mental health infrastructure almost certainly have significant underdiagnosis. The variation in global numbers tells us more about healthcare systems than about biology.
What the Data Actually Tells Us
Autism is a neurodevelopmental condition rooted in brain development that begins before birth. There is no credible evidence that any racial or ethnic group is inherently more or less likely to be autistic. The differences in prevalence data are driven almost entirely by who has access to evaluation, how early children are screened, whether clinicians recognize autism across diverse presentations, and whether families feel supported in pursuing a diagnosis.
The median age of first autism diagnosis in the U.S. is about 47 months, or just under 4 years old. Children who also have an intellectual disability tend to be identified earlier (around 43 months), likely because their delays are more apparent. Children without intellectual disability are diagnosed later, at around 49 months. These averages mask wide variation by geography and demographics: children in some California sites are diagnosed at 36 months, while those in parts of Texas wait until nearly 70 months. That 3-year gap between the fastest and slowest sites, within the same country, illustrates how much diagnosis depends on local resources rather than the condition itself.
The closing of the racial gap in U.S. autism prevalence is largely a success story. It means more children who need support are being identified. But persistent delays in diagnosis for Black and Hispanic children mean many are still missing years of early intervention that could make a meaningful difference in their development.